Hung-Kai (Kevin) Chen

Hung-Kai (Kevin) Chen

Company: Elixiron Immunotherapeutics

Job title: Chairman & Chief Executive Officer


Utilizing Small Molecular Inhibitors to Target & Reduce Neuroinflammation 9:30 am

Focusing on CSRR1 inhibitors to understand how to modulate microglia phenotypes similar to macrophage Understanding why CSFR1 has an improved safety profile to communicate the importance of safety profiles when developing new targets for inflammation Unpicking how to promote neuroprotective functions when developing therapeutics to help improve the next generation of drug developmentRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.